Brolucizumab Monotherapy in Idiopathic Polypoidal Choroidal Vasculopathy:A Case Report
Brolucizumab a humanized single-chain antibody fragment targeting VEGF-A is approved for neovascular age-related macular degeneration nAMD and is being studied for other retinal conditions including polypoidal choroidal vasculopathy PCV. This case report presents a 79-year-old I...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Rajiv Gandhi University of Health Sciences
2025-01-01
|
| Series: | RGUHS Journal of Medical Sciences |
| Online Access: | https://journalgrid.com/view/article/rjms/12434377 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Brolucizumab a humanized single-chain antibody fragment targeting VEGF-A is approved for neovascular age-related macular degeneration nAMD and is being studied for other retinal conditions including polypoidal choroidal vasculopathy PCV. This case report presents a 79-year-old Indian male with idiopathic PCV in the right eye characterized by diminished vision and a large serous pigment epithelial detachment PED 1092 mum. He was treated with a pro re nata PRN regimen of intravitreal Brolucizumab 6 mg0.05 ml. After the first injection PED reduced to 68 mum but later resurfaced 423 mum requiring a second injection. Subsequent follow-ups showed fluctuations in fluid levels necessitating a third injection after which complete resolution was observed. This case highlights Brolucizumabrsquos effectiveness in managing serous PED in IPCV with repeated administration improving long-term fluid resolution. |
|---|---|
| ISSN: | 2231-1947 2581-7248 |